Publications


Supratek’s research has produced more than 100 articles, authored by its scientists, which have appeared in major peer reviewed publications. The covered subjects include oncology, oral bioavailability, clinical trials, biological response modifiers and drug carriers, enhancing CNS bioavailability, and combinatorial chemistry.

The following links provide some selected publications pertinent to the lead product and Supratek’s two platforms:
    • 1.ALAKHOV, V., et al. (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids and Surfaces B: Biointerfaces 16, 113-134.
    • 2.MINKO T., et al. (2005) Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control Release 105, 269-278.
    • 3.DANSON S., et al. (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90, 2085-2091.
    • 4.ARMSTRONG A., J., et al. (2006) SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4080.
    • 1.KABANOV, A. & ALAKHOV, V. (2000) Micelles of amphiphilic block copolymers as vehicles for drug delivery. In: Amphiphilic Block Copolymers. Self-Assembly and Applications (P. Alexandritis & B. Lindman, eds.), Elsevier Science, 347-376.
    • 2.ALAKHOV, V., PIETRZYNSKI, G. & KABANOV, A. (2001) Combinatorial approaches to formulation development, Current Opinion in Drug Discovery and Development, Vol. 4 (4), 493-501.
    • 3.ALAKHOV, V., KLINSKI, E., LEMIEUX, P., PIETRZYNSKI, G. & KABANOV, A. (2001) Block copolymeric Biotransport carriers as versatile vehicles for drug delivery, Expert. Opin. Biol. Ther., 1 (4), 583-602.
    • 4.KABANOV, A.V. & ALAKHOV, V.YU. (2002) Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers, Critical Reviews: Therapeutical Drug Carrier Systems, 19 (1), 1-73.



View in: Mobile | Standard